China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S
03320: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$5.80 | Tccrccm | Xdfqbwvv |
CR Pharma’s Full-Year Results In Line, Shares Trading at Fair Value
Narrow-moat CR Pharma's full-year results were in line with our expectations. Revenue in the second half and full-year was HKD 129 billion and HKD 254 billion, respectively, or 5% and 7.3% year-on-year growth. Core operating profit margin (calculated with cost of sales, sales and administrative expense, research and development, other income, and trade receivables impairment) for the full year improved 22 basis points to 4.8%.